Transactions
BroadOak Partners and its bankers have built a successful track record of completing M&A transactions in the life sciences industry
| Date | Client | Transaction | $(MM) |
|---|---|---|---|
| 6/2010 |  |
Acquisition of Hyaluron, Inc. | $27 |
| 4/2010 |  |
Acquisition of GlobalStem, Inc. | NA |
| 12/2009 |  |
Sale of in-vivo preclinical CRO services business to Taconic Farms, Inc. | $11 |
| 10/2009 |  |
Sale of Alpha Innotech Corp. to Cell Biosciences, Inc. | $20 |
| 10/2009 |  |
Collaboration and license agreement with Novartis | N/A |
| 8/2009 |  |
Sale of non-core assets to Intrexon Corporation | N/A |
| 3/2009 |  |
Sale of Assay Designs, Inc. to Enzo Biochem, Inc. | $12 |
| 10/2008 |  |
Sale of Semrock Inc. to IDEX Corp. | $60 |
| 4/2008 |  |
Acquisition of biodefense vaccines business from Avecia Biologics Limited | $40 |
| 6/2007 |  |
Sale of Fluorescent Detection Products Business | N/A |
| 7/2006 |  |
Sale of In Vitro Technologies, Inc to Celsis International Plc | $30 |
| 3/2006 |  |
Acquisition of sales and marketing rights to EpiPen in Canada from Allerex Laboratory | $25 |
| 12/2005 |  |
Acquisition of Control Delivery Systems | $104 |
| 10/2005 |  |
Sale of NovaScreen Biosciences to Caliper Life Sciences | $22 |
| 10/2005 | |
Merger with xtrana | $20 |
| 7/2004 |  |
Sale of high content screening instrumentation company to BD Biosciences | $25 |
| 11/2001 |  |
Sale of publicly traded medical device company to Johnson & Johnson | $1,300 |
| 7/2001 |  |
Sale of Sybron Biochemical Division to Novozymes | N/A |
| 5/2001 |  |
Sale of publicly traded medical device company to Gyrus Group | $56 |
| 2/2001 |  |
Sale of Munich based medical device company to ResMed | $67 |
| 11/2000 |  |
Implementation of Shareholders Rights Plan | N/A |
| 8/2000 |  |
Acquisition of publicly traded drug discovery tools company LJL BioSystems | $349 |